Truvestments Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Truvestments Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$482	Hold	23	–	–	﹤0.01%	1092
2025 Q4	$529	Sell	23 -86	-79%	-$2.83K	﹤0.01%	949
2025 Q3	$3.28K	Hold	109	–	–	﹤0.01%	878
2025 Q2	$3.96K	Hold	109	–	–	﹤0.01%	761
2025 Q1	$3.95K	Hold	109	–	–	﹤0.01%	779
2024 Q4	$4.59K	Hold	109	–	–	﹤0.01%	711
2024 Q3	$6.05K	Buy	+109	New	+$5.55K	﹤0.01%	658
2024 Q2	–	Sell	-158	Closed	-$7.38K	–	571
2024 Q1	$7.38K	Hold	158	–	–	﹤0.01%	519
2023 Q4	$7.56K	Hold	158	–	–	﹤0.01%	540
2023 Q3	$5.63K	Hold	158	–	–	﹤0.01%	502
2023 Q2	$7.29K	Hold	158	–	–	﹤0.01%	487
2023 Q1	$6.34K	Buy	158 +87	+123%	+$3.73K	﹤0.01%	481
2022 Q4	$3.29K	Hold	71	–	–	﹤0.01%	626
2022 Q3	$3K	Hold	71	–	–	﹤0.01%	522
2022 Q2	$4K	Buy	+71	New	+$4.37K	﹤0.01%	507
2022 Q1	–	Sell	-37	Closed	-$3K	–	454
2021 Q4	$3K	Hold	37	–	–	﹤0.01%	531
2021 Q3	$3K	Hold	37	–	–	﹤0.01%	511
2021 Q2	$4K	Hold	37	–	–	﹤0.01%	489
2021 Q1	$4K	Sell	37 -11	-23%	-$1.5K	﹤0.01%	545
2020 Q4	$6K	Buy	+48	New	+$5.69K	﹤0.01%	480
2019 Q4	–	Sell	-85	Closed	-$4K	–	471
2019 Q3	$4K	Sell	85 -9	-10%	-$489	﹤0.01%	606
2019 Q2	$6K	Hold	94	–	–	﹤0.01%	599
2019 Q1	$7K	Buy	+94	New	+$5.37K	0.01%	565
2018 Q3	$7K	Buy	+97	New	+$7.89K	﹤0.01%	706

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Truvestments Capital's RARE Position: Q1 2026 in Review

Truvestments Capital held its Ultragenyx Pharmaceutical (RARE) position steady in Q1 2026 at 23 shares worth $482. The position accounts for ﹤0.01% of the portfolio, ranked #1092.

Truvestments Capital first reported a position in RARE in Q3 2018 and has held it in 24 quarters since. The position peaked at $7.56K in Q4 2023. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Truvestments Capital held 23 shares of Ultragenyx Pharmaceutical worth $482 as of Q1 2026.
Truvestments Capital left its Ultragenyx Pharmaceutical share count unchanged in Q1 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #1092 holding.
Truvestments Capital first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and has held it in 24 quarters since.
Truvestments Capital's Ultragenyx Pharmaceutical position peaked at $7.56K in Q4 2023.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.